Privium Fund Management B.V. cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 55.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 215,506 shares of the company's stock after selling 268,994 shares during the quarter. Roivant Sciences makes up about 0.6% of Privium Fund Management B.V.'s portfolio, making the stock its 26th largest position. Privium Fund Management B.V.'s holdings in Roivant Sciences were worth $2,549,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. US Bancorp DE grew its holdings in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after buying an additional 1,948 shares during the last quarter. GAMMA Investing LLC boosted its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Quarry LP raised its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company's stock worth $87,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after buying an additional 6,667 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Roivant Sciences Price Performance
Shares of ROIV traded down $0.18 during mid-day trading on Friday, hitting $10.79. The stock had a trading volume of 15,739,544 shares, compared to its average volume of 5,630,885. Roivant Sciences Ltd. has a 52 week low of $9.93 and a 52 week high of $13.06. The business has a fifty day moving average price of $10.78 and a 200-day moving average price of $11.46. The firm has a market cap of $7.70 billion, a P/E ratio of -71.93 and a beta of 1.26.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $18.08.
Read Our Latest Stock Analysis on ROIV
Insider Activity at Roivant Sciences
In other news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 1,875,586 shares of company stock worth $21,491,661. 7.90% of the stock is owned by company insiders.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
